Delving into the Latest Updates on Inflazyme Pharmaceuticals with Synapse

Overview

Tags

Cardiovascular Diseases

Other Diseases

Recombinant protein

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Top 5 Drug Type	Count

Recombinant protein	1

Top 5 Target	Count

C3(Complement C3)	1

AbstractNK cell-mediated cytotoxicity of target cells is the result of a balance between the activating and inhibitory signals provided by their respective ligand-receptor interactions. In our current study, we have investigated the significance of CD59 on human target cells in modulating this process. A range of CD59 site-specific Abs were used in NK cytotoxicity blocking studies against the CD59-expressing K562 target cell line. Significantly reduced cytotoxicity was observed in the presence of Abs previously shown to lack blocking capacity for C-mediated lysis. We investigated the consequences for alternative membrane attachment modalities, namely bis-myristoylated-peptidyl (BiMP) and GPI anchoring, on CD59-negative U937 cells. Expression of GPI-anchored CD59 either via transfection or incorporation rendered U937 targets more susceptible to NK cytotoxicity, whereas incorporation of CD59 via a BiMP anchor to similar levels did not alter susceptibility to NK cytotoxicity. Localization of both BiMP- and GPI-anchored CD59 proteins was shown to be within the lipid raft microdomain. A role for the GPI anchor and independence from glycosylation status was confirmed by expression of transmembrane-anchored CD59 or unglycosylated CD59 and by testing in NK cytotoxicity assays. To investigate mechanisms, we compared the signaling capacity of the various forms of expressed and incorporated CD59 following Ab cross-linking in calcium flux assays. GPI-anchored CD59, with or without glycosylation, mediated activation events, whereas CD59 forms lacking the GPI anchor did not. The data show that the increased susceptibility of target cells expressing CD59 to NK cytotoxicity requires GPI anchor-mediating signaling events, likely mediated by interactions between GPI-anchored CD59 on targets and NK receptors.

100 Deals associated with Inflazyme Pharmaceuticals

Login to view more data

100 Translational Medicine associated with Inflazyme Pharmaceuticals

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

13

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Mirococept ( C3 )	Myocardial Reperfusion Injury More	Phase 3
GD-4040	Thrombosis More	Discontinued
V-19 ( prothrombin )	Thrombosis More	Discontinued
IPL-423088 ( PDE4 )	Inflammatory Bowel Diseases More	Discontinued
IPL-512602	Asthma More	Discontinued